Annual Report 2010/11 - Sonova
Annual Report 2010/11 - Sonova
Annual Report 2010/11 - Sonova
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
6<br />
<strong>Sonova</strong> Group<br />
<strong>Sonova</strong> – the hearing care company<br />
<strong>Sonova</strong> Holding AG develops, manufactures and distributes solutions for better<br />
hearing. With its comprehensive technological expertise, its extensive brand<br />
and product portfolio and its global distribution presence, <strong>Sonova</strong> is in an excellent<br />
position to serve the fast-growing market for hearing-related products.<br />
The <strong>Sonova</strong> Group, which was formed from Phonak Holding<br />
AG on August 1, 2007, has over 60 years of experience in<br />
hearing technology. The current portfolio includes hearing<br />
systems distributed under the Phonak, Unitron, Lyric, and<br />
Sona brands; implant solutions from Advanced Bionics and<br />
Phonak Acoustic Implants; wireless communication and<br />
radio technologies, and hearing protection solutions from<br />
Phonak Communications.<br />
SONOVA AT A GLANCE – KEY FIGURES FOR <strong>2010</strong>/20<strong>11</strong><br />
— EBITA: CHF 326.6 million<br />
— EBITA margin: 20.2%<br />
— Cash-based basic earnings<br />
per share: CHF 4.27<br />
— Operating free cash flow: CHF 221.5 million<br />
90<br />
countries –<br />
worldwide presence<br />
As the industry’s technology leader, <strong>Sonova</strong> has more than<br />
7,800 employees and works daily to help people throughout<br />
the world hear better and enjoy a higher quality of life.<br />
With investments of CHF 107 million in research and development<br />
in the <strong>2010</strong>/20<strong>11</strong> financial year, <strong>Sonova</strong> has made<br />
a commitment to innovation over the long term.<br />
With a comprehensive portfolio and a strategic focus on<br />
core competencies, the Group plans to further increase<br />
its sales and EBITA margin in the coming years and to grow<br />
faster than the market.<br />
1.617<br />
Sales in CHF billion<br />
— ROCE: 19.0%<br />
— ROE: 17.7%